Compare Vanguard Information Technology Index Fund ETF (VGT) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Information Technology Index Fund ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? Vanguard Information Technology Index Fund ETF trades at $120.77, while Vertex Pharmaceuticals Incorporated trades at $521.58 (market cap $134.06B). Which is the better fit depends on your goals.
| VGT | VRTX | |
|---|---|---|
52-Week High | $125.77 | $557.96 |
52-Week Low | $83.59 | $376.62 |
Market Cap | — | $134.06B |
Sector | — | Health |
Enterprise Value | — | $128.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VGT trades at $121.05, showing modest daily weakness with a 0.18% decline. Technical indicators signal a bullish trend with strong moving average support, while oscillators remain neutral. Recent institutional buying activity from firms like Arcus Capital Partners and Guardian Wealth Advisors highlights strong professional interest in the technology ETF.
The ETF's concentrated exposure to AI leaders like Nvidia and Broadcom provides growth potential but also concentration risk. While technical momentum remains positive, investors should monitor semiconductor sector volatility and competitive pressures within the technology landscape that could impact future returns.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with an 86% gross margin and 35% net margin, supported by $12.0B revenue in 2025. Recent acquisition of Crinetics Pharmaceuticals expands its pipeline, while analyst consensus remains strongly bullish with an 85.7% buy rating and a $548.78 price target.
Outlook is positive driven by revenue growth and pipeline expansion, but risks include clinical setbacks and competition. The stock offers upside to the consensus target, with cash flow recovery in 2025 signaling operational strength. Investors should weigh high valuation multiples against earnings consistency and market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Information Technology Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
